JRCT ID: jRCT2080220293
Registered date:24/08/2006
Basic Information
Recruitment status | |
---|---|
Health condition(s) or Problem(s) studied | Ulcerative colitis |
Date of first enrollment | 24/08/2006 |
Target sample size | |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : TA-650 (Infliximab) INN of investigational material : Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for Investigational material : Intravenous drip infusion |
Outcome(s)
Primary Outcome | Efficacy (clinical response), Safety and Pharmacokinetics |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | >= 16age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | [Inclusion criteria] Patients with active ulcerative colitis, who have failed to response, have failed to successfully taper or have medical complications to other existing medications, 16 years and above, male and female. [Exclusion criteria] Patients who have received infliximab in the past, have a history of serious infection which caused hospitalization within 6 months before the registration, have an active tuberculosis, have a complication or a history of malignancy within 5 years before the registration. |
Exclude criteria |
Related Information
Primary Sponsor | Mitsubishi Tanabe Pharma Corporation |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | JapicCTI-060298 |
Contact
Public contact | |
Name | |
Address | cti-inq-ml@ml.mt-pharma.co.jp |
Telephone | |
Affiliation | Mitsubishi Tanabe Pharma Corporation. |
Scientific contact | |
Name | |
Address | |
Telephone | |
Affiliation |